N-conjugate modification of nucleosides and nucleotides generally refers to the introduction of a conjugated structure by modifying the nitrogen atom in the base. Common N-conjugate modification reactions include N-alkylation, N-arylation, and N-allylation. N-alkylation modifications are formed by introducing an alkyl group to the nitrogen atom of the nucleoside base through nucleophilic substitution reactions. For example, the alkyl group is attached to the nitrogen atom of the base using an alkylophilic reagent (e.g., alkyl halide or alkyl lithium) in a reaction with the base. The N-arylation reaction is similar to the N-alkylation reaction in that an aryl group is introduced via a nucleophilic substitution reaction. The N-allylation reaction utilizes a base catalyst to catalyze an addition reaction between an allyl reagent and the base, thereby introducing an allyl group to the nitrogen atom of the base, resulting in a modification that is N-allylated.
The key technologies of this service are N-alkylation, N-arylation, and N-allylation modifications, achieved through nucleophilic substitution and addition reactions using specialized reagents including alkyl/aryl halides and lithium compounds, with precise hydroxyl protection strategies (e.g., silyl, ester, or acetyl groups) and structural verification via NMR and mass spectrometry.
CD BioGlyco has successfully established a Glyco™ Synthesis Platform to provide clients with a complete Custom Sugar-nucleotides Synthesis Service. Our professional nucleoside & nucleotide Modification Service and Oligosaccharide Modification Service have received wide recognition in the field of glycochemistry. The details of our base-based N-conjugation modification are as follows:
DOI.: 10.1038/s41557-023-01320-z
Journal: Nature Chemistry
Published: 2023
Results: This study introduces SAMURI, an engineered ribozyme that enables site-specific N-alkylation of nucleosides in RNA using a synthetic, stabilized SAM analogue (ProSeDMA). The authors designed ProSeDMA as a bioorthogonal cofactor resistant to degradation, facilitating efficient transfer of propargyl groups to target adenosines via N3-alkylation—confirmed through atomic mutagenesis and mass spectrometry. SAMURI achieves near-quantitative conversion under physiological conditions (including low Mg2+), enabling its expression in HEK293T cells for intracellular RNA propargylation (17% efficiency) with minimal cytotoxicity. The installed propargyl group serves as the smallest bioorthogonal tag for downstream click chemistry functionalization (e.g., fluorophores, affinity probes). This platform advances RNA modification services by offering precise, cell-compatible tools for labeling, structural analysis, and functional genomics.
Our modification services enable precision-driven installation of bioorthogonal handles (e.g., azides, alkynes) onto nucleobases, creating chemoselective anchors for payload linkage while preserving nucleic acid functionality. To extend this atomic-level control into antibody therapeutic engineering, we offer the Glycosylation Site-specific ADC Development Platform—leveraging the conserved Fc N-glycan at Asn-297 for site-directed toxin conjugation. This unified approach ensures DAR homogeneity and enhanced pharmacokinetics through:
CD BioGlyco provides clients with a full range of customized nucleoside & nucleotide N-conjugation modification services based on base. Our experts in organic synthesis and glycobiology can also help you design synthetic pathways according to your needs and provide analytical services for the final product. If you are interested in our services, please feel free to contact us for more details.
Reference